| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
QuantaMatrix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,850.00 |
| 52 Week High | ₩23,700.00 |
| 52 Week Low | ₩3,360.00 |
| Beta | 0.12 |
| 11 Month Change | -39.20% |
| 3 Month Change | 137.92% |
| 1 Year Change | 61.48% |
| 33 Year Change | -30.88% |
| 5 Year Change | n/a |
| Change since IPO | -59.13% |
Recent News & Updates
Is QuantaMatrix (KOSDAQ:317690) Using Debt In A Risky Way?
Jul 19
What Type Of Shareholders Make Up QuantaMatrix Inc.'s (KOSDAQ:317690) Share Registry?
Mar 10Shareholder Returns
| A317690 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 12.3% | 1.6% | 2.2% |
| 1Y | 61.5% | 31.5% | -2.3% |
Return vs Industry: A317690 exceeded the KR Biotechs industry which returned 31.1% over the past year.
Return vs Market: A317690 exceeded the KR Market which returned -2.9% over the past year.
Price Volatility
| A317690 volatility | |
|---|---|
| A317690 Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A317690's share price has been volatile over the past 3 months.
Volatility Over Time: A317690's weekly volatility has increased from 13% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 92 | Sung Hoon Kwon | www.quantamatrix.com |
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. The company was founded in 2010 and is based in Seoul, South Korea.
QuantaMatrix Inc. Fundamentals Summary
| A317690 fundamental statistics | |
|---|---|
| Market cap | ₩162.89b |
| Earnings (TTM) | -₩17.94b |
| Revenue (TTM) | ₩3.60b |
45.2x
P/S Ratio-9.1x
P/E RatioIs A317690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A317690 income statement (TTM) | |
|---|---|
| Revenue | ₩3.60b |
| Cost of Revenue | ₩2.55b |
| Gross Profit | ₩1.06b |
| Other Expenses | ₩19.00b |
| Earnings | -₩17.94b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09k |
| Gross Margin | 29.27% |
| Net Profit Margin | -497.76% |
| Debt/Equity Ratio | 155.9% |
How did A317690 perform over the long term?
See historical performance and comparison